Your browser doesn't support javascript.
loading
SCUBE1 is associated with thrombotic complications, disease severity, and in-hospital mortality in COVID-19 patients.
Toprak, Kenan; Kaplangoray, Mustafa; Palice, Ali; Tascanov, Mustafa Begenç; Inanir, Mehmet; Memioglu, Tolga; Kök, Zafer; Biçer, Asuman; Demirbag, Recep.
Afiliación
  • Toprak K; Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, Turkey. Electronic address: kentoprak@hotmail.com.
  • Kaplangoray M; Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkey.
  • Palice A; Mehmet Akif Inan Training and Research Hospital, Sanliurfa, Turkey.
  • Tascanov MB; Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, Turkey.
  • Inanir M; Abant Izzet Baysal University, Medical Faculty, Cardiology Department, Bolu, Turkey.
  • Memioglu T; Abant Izzet Baysal University, Medical Faculty, Cardiology Department, Bolu, Turkey.
  • Kök Z; Izzet Baysal Training and Research Hospital, Bolu, Turkey.
  • Biçer A; Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, Turkey.
  • Demirbag R; Department of Cardiology, Faculty of Medicine, Harran University, Sanliurfa, Turkey.
Thromb Res ; 220: 100-106, 2022 12.
Article en En | MEDLINE | ID: mdl-36334396
INTRODUCTION: COVID-19 disease, which has recently become an important cause of mortality and morbidity all over the world, is remarkably associated with thrombotic complications. Although many factors are responsible for these increased thrombotic complications in COVID-19 disease, its relationship with a marker that increases the risk of thrombosis such as Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) has not yet been clarified. This is the first study to examine the potential diagnostic and prognostic value of SCUBE1 levels in patients with COVID-19. In this study, we aimed to clarify the relationship between the increased risk of thrombosis and SCUBE1 in the course of COVID-19 disease. MATERIALS AND METHODS: 553 patients with COVID-19 and 553 healthy controls were compared in terms of SCUBE1 levels. Additionally, patients with COVID-19 were divided into two groups according to their SCUBE1 levels and compared in terms of severity of disease, thrombotic complications and in-hospital mortality. RESULTS: SCUBE1 levels were significantly higher in patients with COVID-19 compared to the control group (p < 0.001). Plasma SCUBE1 levels were significantly higher in patients with severe disease and thrombotic complications, those with mild to moderate disease, and those without thrombotic complications (p < 0.001, for both). In addition, SCUBE1 was found to be an independent predictor of in-hospital mortality (p < 0.001). CONCLUSIONS: SCUBE1 may be one of the major determinants of thrombotic complications, which is an increased cause of mortality and morbidity in COVID-19 patients so inhibition of this peptide may be among the therapeutic targets in patients with COVID-19.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombosis / COVID-19 Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Thromb Res Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trombosis / COVID-19 Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Thromb Res Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos